θÖ×Áö/ÖÎÁÆ,Stomach neoplasms/therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎѪ¹ÜÈâÁö,Hepatic angiosarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±Çµ¨¹Ü,Nasobiliary ductÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½»½çÐÔ²¡±ä,borderline lesionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ä¤¶ñÐÔ¼äÆ¤Áö,Malignant peritoneal mesotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʵÐÔ-¼ÙÈéÍ·×´Ö×Áö,solid-pseudopapillary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ç»³åÏ´Òº,Peritoneal washesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Gli1µ°°×,Gli1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ç»Éñ¾­´Ô×èÖÍ,neurolytic celiac plexus blockÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦ÏÙÁö,Rectal adenomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ×ÐÔ¼¡ÏËάĸϸ°ûÖ×Áö,Inflammatory myofibroblastic tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÕûºÏËØ¦Áv,integrin ¦ÁvÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« cyclinD1µ°°×ÖÊ,cyclinD1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¡ÀíÑ§ÌØµã,pathological characteristicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±µ¼ÁÔìÓ°,barium mealÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼õÁöÊõ,cytoreductive surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Åöײ°©,Collision carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²ºÍ²¡Àí,Clinic and pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍíÆÚêÚÃŰ©,advanced cardiac carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎÔà×ªÒÆÁö,liver metastasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÈÏÙµ¼¹ÜÏÙ°©,Pancreatic ductal adenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î¹¦ÄÜʧ´ú³¥,liver function discompensationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« U¹Ü,U tubeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇøÓòÐÔÒÈÏÙÇгýÊõ,regional pancreatectomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ôç·¢ÏÖ,early detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÝÐýË®µ¶,Helix hydro-jetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¸Âö³åµç³¡,steep pulsed electric field(SPEF)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦Ö×Áö/ÖÎÁÆ,gastrointestinal neoplasms/therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔθ¶ñÐÔÁܰÍÁö,Primary gastric malignant lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ°©Ö×Áö,stomach neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºôÎü¶¯¶È,Breathing movementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊõÖб£ÎÂ,Intraoperative warmingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« H22¸Î°©ÒÆÖ²Áö,murine hepatoma H22 liver cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÌÎå¼ÓÔíß°,Acanthopanax senticousus saponinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Æ¼¤ËØÊÜÌå2,estrogen receptor 2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÆËã»úÌå²ã³ÉÏñ(CT),Computed tomography(CT)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒÖÖÆµ°°×Àà,Tumor Suppressor ProteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×µÄ±í´ï,protein expressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MHCC97-Hϸ°û,MHCC97-H cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒò×é²»Îȶ¨,genomic instabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÖÜÉÏÆ¤Ñùϸ°ûÁö,Perivascular epithelioid cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ¼²²¡/Íâ¿ÆÊÖÊõ,stomach diseases/surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¦ÏµÄ¤ÉϾ²Âö/Íâ¿ÆÑ§,Superior Mesentery Vein/surgÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØ¸¹ÁªºÏÇпÚ,thoracoabdominal incisionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö÷¶¯ºôÎü¿ØÖƼ¼Êõ,Active breathing controlÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÞ²¡Éú´æÆÚ,disease-free survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯Âö»¯ÁÆË¨ÈûÊõ,transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« VX2¸Î°©,VX_2 Liver tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˫ԭ·¢°©,multiple primary cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²×ªÒÆ,ovarian metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СÊó¸Î°©H22,Murine Hepatoma 22Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÖÂþÐÍθ°©,diffuse-type gastric carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¢Ì嶨ÏòÕÕÉä,stereotactic irradiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²à²àÎǺÏ,side-to-side neurorrhaphyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« cdc25Á×Ëáø,cdc25 phosphataseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÈÏÙ°©Ï¸°û,Pancreatic cancer cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±£Áô¸ØÃÅ,sphincter preservationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 3ÖÜ·½°¸,3-week regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CD147µ°°×,CD147 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÈÐݿ˵°°×90ÒÖÖÆ¼Á,heat shock protein 90 inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾±¶Îʳ¹Ü°©,Cervical esophageal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ(³¦)ÑÊÎǺÏÊõ,Gastric(enteric)-pharyngeal anastomosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÙÅÝϸ°û°©,acinar cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ä¤ºóÉñ¾­ÇÊÁö,retroperitoneal schwannomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TIMP3»ùÒò,TIMP3 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MMP-2mRNA,MMP-2 mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ßΣģÐÍ,High risk modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÈ¼ÁÁ¿ÇúÏß,Isodose CurveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Àà°©Áö/Íâ¿ÆÑ§,carcinoid tumor/surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎβҶ,caudate lobeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÐÔÄÉÃ×΢Á£,Magnetic nanoparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅèÇ»×ÔÖ÷Éñ¾­±£Áô,Pelvic autonomic nerve preservationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ÂɳÀû²¬/ÖÎÁÆÓ¦ÓÃ,Oxaliplatin/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉúÎïѧÖá,Biological axisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢²¨µ¶,Microwave KnifeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒȵºËØÑùÉú³¤Òò×Ó¢ñÊÜÌå,Insulin-like growth factor-¢ñ receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Wnt/¦Â-cateninͨ·,Wnt/¦Â-catenin pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Î÷»Æ½ºÄÒ,Xihuang capsulesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÖÊÁö/Õï¶Ï,Stromal Tumor/diagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÖÊÁö/Íâ¿ÆÑ§,Stromal Tumor/surgÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« GGT»ùÒò,GGT geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ת»¯Éú³¤Òò×Ó¦Â/ѪҺ,Transforming growth factor beta/bloodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θÀà°©,gastric carcinoidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î¶¯Âö²å¹Ü»¯ÁÆË¨Èû,Transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹Èë׸ÊëÄ-S-×ªÒÆÃ¸¦Ð,glutathione-S-transferase ¦ÐÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Êõºó¾Ö²¿¸´·¢,Postoperate local recurrenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËθ°©,Human gastric carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÙÁöÐÔÏ¢Èⲡ,adenomatous polyposisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³öÉú˳Ðò·ÖÎö,birth order analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÃVX2,rabbit VX_2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« °¢Ë¾Æ¥ÁÖ-ÑÌõ£°·-пÂçºÏÎï,aspirin-niacinamide-zinc complexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¤³Ìϸ°ûÖê,Engineering cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Å´ó³¦¾µ,Magnifying colonoscopyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Æ¼¤ËØÊÜÌåÏà¹ØÊÜÌå,Estrogen receptor-related receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²Ö×Áö/¼Ì·¢ÐÔ,ovarian neoplasms/secondaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÔÅòʽ´øÄ¤Ö§¼Ü,Self-expanding covered stentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔ¸Îϸ°ûÐԸΰ©,primary hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ä¤ºóÖ×Áö/Õï¶Ï,retroperitoneal neoplasms/DIÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÐÂÉúѪ¹ÜÉú³É,tumor angiogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ö×ÁöÒ©(ÖÐÒ©)/Ò©Àíѧ,antineoplastic drugs (TCD)/pharmacologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«